Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 889b07171cdcc3f58f063aae6b22c626
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book does nothing less than lay out the state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities. The sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to derive more efficient cancer drugs 200 pp. Englisch. N° de réf. du vendeur 9783642068348
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. N° de réf. du vendeur 5045923
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 12049314-n
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book. N° de réf. du vendeur 9783642068348
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In English. N° de réf. du vendeur ria9783642068348_new
Quantité disponible : Plus de 20 disponibles
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Targeted Interference with Signal Transduction Events | B. Groner | Taschenbuch | Recent Results in Cancer Research | ix | Englisch | 2010 | Springer | EAN 9783642068348 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. N° de réf. du vendeur 107212033
Quantité disponible : 5 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow¿s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 200 pp. Englisch. N° de réf. du vendeur 9783642068348
Quantité disponible : 1 disponible(s)
Vendeur : Books Puddle, Woodside, NY, Etats-Unis
Etat : New. pp. 200. N° de réf. du vendeur 263071821
Quantité disponible : 4 disponible(s)
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 12049314-n
Quantité disponible : 1 disponible(s)